Single-center Veterans Hospital Heart Failure Study: Heart Failure Readmissions And New-York Heart Association (NYHA) Class Related To Increased Mortality
HFSA ePoster Library. Khadilkar A. 09/10/21; 343574; 332
Arjun Khadilkar
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Background: Patients with concomitant anemia and congestive heart failure tend to have worse outcomes. The prevalence and clinical risk of significant anemia in patients receiving durable LVAD remain unknown.
Methods: We retrospectively analyzed patients who underwent LVAD implantation between 2014 and 2018. The association between hemoglobin level at the time of index discharge and the one-year composite endpoint of heart failure readmissions or hemocompatibility-related adverse events was investigated.
Results: A total of 167 patients (57 [48, 66] years old, 123 males) were included and stratified into a classification of severe anemia (hemoglobin <9.7 g/dL, N = 99) or non-severe anemia (N = 68). The severe anemia group had a higher one-year incidence of the composite endpoint (56% versus 36%, p = 0.013; Figure 1) with a hazard ratio of 1.71 (95% confidence interval 1.07-2.75) after multivariate adjustment. Patients with severe anemia also experienced suboptimal LVAD unloading. Conclusions: Severe anemia was prevalent in LVAD patients and associated with a greater risk of heart failure and hemocompatibility-related adverse events. The optimal threshold for therapeutic intervention in response to anemia post-LVAD needs further investigation.
Methods: We retrospectively analyzed patients who underwent LVAD implantation between 2014 and 2018. The association between hemoglobin level at the time of index discharge and the one-year composite endpoint of heart failure readmissions or hemocompatibility-related adverse events was investigated.
Results: A total of 167 patients (57 [48, 66] years old, 123 males) were included and stratified into a classification of severe anemia (hemoglobin <9.7 g/dL, N = 99) or non-severe anemia (N = 68). The severe anemia group had a higher one-year incidence of the composite endpoint (56% versus 36%, p = 0.013; Figure 1) with a hazard ratio of 1.71 (95% confidence interval 1.07-2.75) after multivariate adjustment. Patients with severe anemia also experienced suboptimal LVAD unloading. Conclusions: Severe anemia was prevalent in LVAD patients and associated with a greater risk of heart failure and hemocompatibility-related adverse events. The optimal threshold for therapeutic intervention in response to anemia post-LVAD needs further investigation.
Background: Patients with concomitant anemia and congestive heart failure tend to have worse outcomes. The prevalence and clinical risk of significant anemia in patients receiving durable LVAD remain unknown.
Methods: We retrospectively analyzed patients who underwent LVAD implantation between 2014 and 2018. The association between hemoglobin level at the time of index discharge and the one-year composite endpoint of heart failure readmissions or hemocompatibility-related adverse events was investigated.
Results: A total of 167 patients (57 [48, 66] years old, 123 males) were included and stratified into a classification of severe anemia (hemoglobin <9.7 g/dL, N = 99) or non-severe anemia (N = 68). The severe anemia group had a higher one-year incidence of the composite endpoint (56% versus 36%, p = 0.013; Figure 1) with a hazard ratio of 1.71 (95% confidence interval 1.07-2.75) after multivariate adjustment. Patients with severe anemia also experienced suboptimal LVAD unloading. Conclusions: Severe anemia was prevalent in LVAD patients and associated with a greater risk of heart failure and hemocompatibility-related adverse events. The optimal threshold for therapeutic intervention in response to anemia post-LVAD needs further investigation.
Methods: We retrospectively analyzed patients who underwent LVAD implantation between 2014 and 2018. The association between hemoglobin level at the time of index discharge and the one-year composite endpoint of heart failure readmissions or hemocompatibility-related adverse events was investigated.
Results: A total of 167 patients (57 [48, 66] years old, 123 males) were included and stratified into a classification of severe anemia (hemoglobin <9.7 g/dL, N = 99) or non-severe anemia (N = 68). The severe anemia group had a higher one-year incidence of the composite endpoint (56% versus 36%, p = 0.013; Figure 1) with a hazard ratio of 1.71 (95% confidence interval 1.07-2.75) after multivariate adjustment. Patients with severe anemia also experienced suboptimal LVAD unloading. Conclusions: Severe anemia was prevalent in LVAD patients and associated with a greater risk of heart failure and hemocompatibility-related adverse events. The optimal threshold for therapeutic intervention in response to anemia post-LVAD needs further investigation.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}